Type I, II, and III inositol-1,4,5-trisphosphate (InsP 3 ) receptors are expressed selectively in different cell lines and tissues. We examined whether type I, II, and III InsP 3 receptors differ in ligand-binding affinity and whether such differences influence the sensitivity of Ca 2ϩ stores to InsP 3 . Initially, SH-SY5Y human neuroblastoma cells, AR4 -2J rat pancreatoma cells, and RINm5F rat insulinoma cells were studied because these cells express predominantly (Ͼ85%) type I, II, and III receptors, respectively. Immunopurification of receptors from these cell lines and measurement of InsP 3 binding revealed that the rank order of affinity for InsP 3 was type I Ͼ type II Ͼ type III (binding sites were half-maximally saturated at 1.5, 2.5, and 22.4 nM InsP 3 , respectively). Examination of Ca 2ϩ store mobilization in permeabilized cells showed that InsP 3 was equipotent in SH-SY5Y and AR4 -2J cells but was ϳ5-fold less potent in RINm5F cells. In contrast, Ca 2ϩ uptake and InsP 3 -independent Ca 2ϩ release were very similar in the three cell types. The binding affinity of InsP 3 in permeabilized SH-SY5Y, AR4 -2J, and RINm5F cells correlated well with its potency as a Ca 2ϩ -mobilizing agent and with binding affinity to immunopurified type I, II, and III receptors. Thus, InsP 3 receptor binding affinity seems to influence the potency of InsP 3 as a Ca 2ϩ -mobilizing agent. Finally, immunopurification of type I, II, and III receptors from rat tissues revealed that the affinity differences seen in receptors purified from cultured cells are paralleled in vivo. In combination, the data from cell lines and rat tissues reveal that type I, II, and III receptors bind InsP 3 with K d values of ϳ1, ϳ2, and ϳ40 nM, respectively, and that the selective expression of a particular receptor type will influence the sensitivity of cellular Ca 2ϩ stores to InsP 3 .
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InsP 3 receptors play a crucial role in intracellular signaling as they tetramerize to form channels in endoplasmic reticulum membranes that conduct Ca 2ϩ in an InsP 3 -sensitive manner Joseph, 1996) . To date, the coding regions of three mammalian InsP 3 receptor genes have been sequenced, and in rat, their products, termed type I, II, and III receptors, are 2749, 2701, and 2670 amino acids in length, respectively (Mignery et al., 1990; Sudhof et al., 1991; Blondel et al., 1993; Furuichi and Mikoshiba, 1995; Joseph, 1996) . Highly homologous type I, II, and III receptors also are present in other mammals (Yamada et al., 1994; Yamamoto-Hino et al., 1994) .
Analyses of InsP 3 receptor distribution have shown that the type I receptor is expressed in many if not all tissues and in particular is in abundance in neural tissue Joseph, 1996) . In contrast, type II and III receptors generally are less widespread (Joseph, 1996) , but they are prominent in certain tissues; for example, the type II receptor is abundant in liver (Newton et al., 1994; Joseph et al., 1995; Wojcikiewicz, 1995; De Smedt et al., 1997) , and the type III receptor is present at high levels in pancreatic tissue (Blondel et al., 1993 (Blondel et al., , 1994 Nathanson et al., 1994; Wojcikiewicz, 1995) . Indeed, in certain cell types, type II or III receptors may be the predominant form, as has been shown with cells in culture (Wojcikiewicz, 1995; De Smedt et al., 1997) . It also has become evident that type I, II, and III receptors are coexpressed within cells, as demonstrated at the level of mRNA species (Newton et al., 1994; YamamotoHino et al., 1994; De Smedt et al., 1997) and protein (Joseph et al., 1995; Monkawa et al., 1995; Wojcikiewicz, 1995; Yule et al., 1997) and are free to form heterotetrameric associations (Joseph et al., 1995; Monkawa et al., 1995; Wojcikiewicz and He, 1995; Nucifora et al., 1996) .
Characterization of the differences among type I, II, and III receptors is at a preliminary stage, and it is not yet clear what properties are conferred on a cell by the selective expression of a particular receptor type (Joseph, 1996) . Perhaps the most obvious way in which InsP 3 receptors might differ is in their affinity for InsP 3 . As yet, however, the affinities of native type I, II, and III receptors have not been compared directly. Nor is it known how differences among type I, II, and III receptors in binding affinity would influence the sensitivity of cellular Ca 2ϩ stores to InsP 3 . To address these issues, we measured the binding affinity of InsP 3 to immunopurified type I, II, and III receptors and assessed the relationship between binding affinity and the Ca 2ϩ -mobilizing potency of InsP 3 in cultured cells that express predominantly type I, II, or III receptors. Furthermore, we examined InsP 3 binding to receptors immunopurified from rat tissues to determine whether our findings in vitro reflect the situation in vivo. gels were either silver-stained or immunoblotted as described previously (Wojcikiewicz, 1995; Wojcikiewicz and He, 1995) .
InsP 3 binding to immunoprecipitated receptors. A previous study has shown that the Protein A bead/antibody/InsP 3 receptor complex remains intact during radioligand binding studies (Joseph and Samanta, 1993) . Thus, washed beads (100 l) were incubated at 4°for 30 min with [ 3 H]InsP 3 (specific activity, 2-5 Ci/mmol) in 35 mM Tris-base and 1.5 mM EDTA, pH 8.0 (final volume, 200 l). Bound ligand was isolated by vacuum filtration; incubation mixtures were pipetted onto prewetted Whatman (Clifton, NJ) GF/B filters and washed twice with 4 ml of ice-cold 20 mM Tris-base and 1 mM EDTA, pH 8.0. Filters were added to vials with 0.5 ml of water and 5 ml of Ecoscint H (National Diagnostics, Atlanta, GA) and assessed for radioactivity after 48-hr extraction. Nonspecific binding was defined by including Ն10 M nonradioactive InsP 3 in parallel incubations. Specific binding was analyzed with Prism (GraphPAD Software, San Diego, CA), initially fitting data to sigmoid curves of variable slope to determine concentrations that gave half-maximal saturation. The B max values (the maximum number of binding sites) obtained from these analyses were then used to normalize data for presentation in Figs. 2, 3, and 7. Values of K d (the equilibrium dissociation constant) for type I and II receptor preparations then were determined by fitting data to one-site saturation binding curves; for type III receptor preparations, specific binding was fitted to two-site saturation binding curves to define the apparent multiple sites.
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2؉ mobilization and InsP 3 binding in permeabilized cells. SH-SY5Y cells (two dishes) and AR4-2J and RINm5F cells (one dish each) were harvested in 12 ml of HBSE, centrifuged (1000 ϫ g for 2 min), resuspended in 10 ml of ice-cold cytosol buffer (120 mM KCl, 2 mM KH 2 PO 4 , 2 mM MgCl 2 , 10 M EGTA, 2 mM ATP, 20 mM HEPES, pH 7.0), centrifuged again (2000 ϫ g for 2 min at 4°), and resuspended in 2 ml of cytosol buffer. Protein concentration in each cell suspension was then equalized to ϳ2.0 mg/ml; cells were incubated with digitonin (100 g/ml) for 10 min at 4°and then centrifuged (2000 ϫ g for 2 min at 4°). For 45 Ca 2ϩ -mobilization studies, pellets were resuspended in 1.4 ml of cytosol buffer and finally incubated with ϳ0.5 Ci of 45 Ca 2ϩ for 20 min at room temperature. Portions of cell suspensions (100 l) then were added to tubes containing 3 ml of ice-cold cytosol buffer plus stimuli. After 10-300 sec, incubations were terminated by filtration through Whatman GF/B filters, and radioactivity bound to the filters (amount of Ca 2ϩ not mobilized) was assessed after the addition of 4 ml of Ecoscint H and overnight extraction. For binding studies, pellets were washed twice with 2 ml of cytosol buffer, and cell suspensions were incubated with [ 3 H]InsP 3 (specific activity, ϳ1 Ci/mmol) in a final volume of 100 l of cytosol buffer for 15 min at 4°. The mixture then was transferred to filters and washed with 10 ml of ice-cold cytosol buffer. Miscellany. Peroxidase-conjugated antibodies, molecular mass markers, dithiothreitol, protease inhibitors, ATP, InsP 3 , and digitonin were obtained from Sigma Chemical (St. Louis, MO). Protein A/Sepharose CL-4B was from Pharmacia (Piscataway, NJ). 
Results
Binding to InsP 3 receptors immunoprecipitated from cell lines. Previous analysis of a range of cultured cell lines established the InsP 3 receptor content of SH-SY5Y cells to be Ն99% type I; that of AR4-2J cells to be 12% type I, 86% type II, and 2% type III; and that of RINm5F cells to be 4% type I and 96% type III (Wojcikiewicz, 1995) . Thus, for the current study, SH-SY5Y, AR4-2J, and RINm5F cells were Type I, II, and III Inositol-1,4,5-Trisphosphate Receptor Characteristics used as sources of type I, II, and III receptors, respectively. Immunopurification of receptors from these cell lines with the specific antisera CT1, CT2, and CT3 ( Fig. 1) (Wojcikiewicz, 1995) and indicate that some of the InsP 3 receptor complexes purified from AR4-2J and RINm5F cells are heterotetrameric. It is estimated that the type II and III receptor preparations contain ϳ10% and ϳ5% type I receptor, respectively (Wojcikiewicz, 1995; Fig. 1) .
The characteristics of InsP 3 binding to the type I, II, and III receptor preparations were defined (Fig. 2) . Initial analysis ( Fig. 2A) showed that half-maximal saturation of binding sites occurred at 1.5, 2.5, and 22.4 nM InsP 3 , respectively (the values for type II and III receptors being significantly greater than that for type I receptor, p Յ 0.01) and that each receptor type bound approximately equivalent amounts of InsP 3 when saturated (see Fig. 2 legend) . Although Hill slopes were ϳ1, indicating that a single affinity predominated in each preparation, that for the type III receptor preparation (0.86 Ϯ 0.03) was significantly Ͻ1 (p Յ 0.01), indicating that multiple sites might be present (see Fig. 2 legend). Scatchard analysis (Fig. 2B ) confirmed that sites with different affinities were present in the type III receptor preparation. Although it is clear from Fig. 1 that the type II receptor preparation also contains type I receptor, this is not reflected in the Hill slope being Ͻ1 or in curvilinear Scatchard plots, presumably because the affinities of type I and II receptors are so similar. Thus, one-site analysis was used to define K d values for type I and II receptor preparations and two-site analysis was used for the type III receptor preparation. K d values obtained were 1.4 Ϯ 0.2 nM for type I receptor, 2.4 Ϯ 0.2 nM for type II receptor, and 1.1 Ϯ 0.5 and 47.8 Ϯ 7.1 nM for the type III receptor preparation, with the latter site representing 87 Ϯ 2% of total (at least four independent experiments). Both the type II receptor and the predominating low affinity site in the type III receptor preparation (presumably the type III receptor) were of lower affinity than the type I receptor ( p Յ 0.01). Thus, type II and III receptors seem to bind InsP 3 with ϳ2-fold and ϳ30-fold lower affinity than the type I receptor, respectively.
Binding of InsP 3 to type III receptor homotetramers. To establish that binding to the type III receptor preparation was not due to some kind of interaction with the trace amounts of type I receptor present therein (Fig. 1, lane 3) , we sought to purify type III receptor homotetramers by preclearing RINm5F cell lysates of type I/III receptor heterotetramers before immunoprecipitation with CT3. Such an approach was used by Nucifora et al. (1996) . Immunoblots of a control type III receptor preparation (Fig. 3A, lane 1) confirm that both type III and I receptors are present therein. In contrast, when lysates were precleared with CT1, only type III receptor was recovered (Fig. 3A, lane 2) , indicating that type I/III , and RINm5F (lane 3) cell lysates with CT1, CT2, and CT3, respectively, and were electrophoresed in 4% gels and silver stained. Shown is the ϳ150 -400-kDa region of a gel (representative of five independent experiments). The positions to which myosin mass marker (205 kDa) and type I, II, and III receptors migrate, ϳ270, ϳ255, and ϳ260 kDa, respectively (Wojcikiewicz, 1995) , are indicated. receptor heterotetramers were removed and that this preparation consists exclusively of type III receptor homotetramers. Fig. 3B shows that binding to control or type I receptor precleared (homotetrameric) type III receptor preparations was similar but subtly different (half-maximally saturation at ϳ34 and ϳ47 nM InsP 3 , respectively, and Hill slopes of ϳ0.81 and ϳ0.97, respectively). These data and the fact that preclearing reduced maximal binding by only ϳ10% are consistent with removal of trace amounts of a high affinity binding site (the type I receptor) from the type III receptor preparation. Thus, it is clear that RINm5F cell type III receptors do bind InsP 3 and that binding to type I/III receptor heterotetramers does not compromise the conclusions from Fig. 1 regarding type III receptor binding affinity. Finally, it is noteworthy that half-maximal saturation of homotetrameric type III receptors (ϳ47 nM, Fig. 3B ) is identical to the K d value of the low affinity binding site in heterotetramercontaining type III receptor preparations (ϳ48 nM, Fig. 2) .
InsP 3 binding and Ca 2؉ mobilization in permeabilized SH-SY5Y, AR4-2J, and RINm5F cells. We next sought to determine whether the type I, II, and III receptor affinity differences also were seen with membrane-associated receptors and, if so, whether they influenced the sensitivity of Ca 2ϩ stores to InsP 3 . Thus, we measured InsP 3 binding and Ca 2ϩ mobilization in digitonin-permeabilized SH-SY5Y, AR4-2J, and RINm5F cells under identical conditions. Fig. 4 shows that InsP 3 binding affinity differs in the three cell types (half-maximal saturation at 25, 31, and 260 nM, respectively) and that although absolute values of affinity were ϳ1 order of magnitude higher than that seen with immunoprecipitated type I, II, and III receptors (most likely because of differences in buffer composition used in Figs. 4 and 2) , the relative differences between the cell types parallel those among type I, II, and III receptors. This indicates that immunoprecipitated receptors remain in native form despite being solubilized and bound by antibody and validates the conclusions from Fig. 2 .
The potency of InsP 3 as a Ca 2ϩ -mobilizing agent also varied considerably, whereas maximal Ca 2ϩ release was similar for the three cell types (Fig. 5A ). For SH-SY5Y, AR4-2J, and RINm5F cells, EC 50 values were 22 Ϯ 2, 20 Ϯ 2, and 94 Ϯ 6 nM InsP 3 , respectively, and Hill slopes were 1.9 Ϯ 0.1, 1.8 Ϯ 0.1, and 2.0 Ϯ 0.1, respectively (eight independent experiments; Fig. 5A ). Thus, because InsP 3 has similar Ca 2ϩ -releasing potency in SH-SY5Y and AR4-2J cells but is much less potent in RINm5F cells, EC 50 values and binding affinity do correlate (compare Figs. 5A and 4) .
To validate the argument that binding affinity influences potency, other factors that could cause the differences seen in Fig. 5A were examined and discounted. First, variation in Ca 2ϩ release kinetics could influence EC 50 ; however, the rates of InsP 3 -induced Ca 2ϩ efflux were essentially identical for each cell type (Fig. 5B) . Second, the extent to which Ca 2ϩ stores are loaded can influence EC 50 (Parys et al., 1993) ; however, the extent of Ca 2ϩ uptake was very similar for each cell type (Fig. 5, legend) . Third, as-yet-undefined factors might suppress Ca 2ϩ release from RINm5F cells; however, ionomycin, which acts independently of InsP 3 receptors, released Ca 2ϩ to a similar extent (Fig. 5A ) and with similar kinetics (Fig. 5B) in SH-SY5Y, AR4-2J, and RINm5F cells. Furthermore, the characteristics of thapsigargin-induced 45 Ca 2ϩ release in 5-min incubations at 25°were very similar for the three cell types (EC 50 ϭ 0.7 Ϯ 0.1, 0.6 Ϯ 0.1, and 0.9 Ϯ 0.1 M, respectively; five independent experiments). Finally, RINm5F cells could be resistant to or adversely affected by digitonin. However, data essentially identical to those shown in Fig. 5A were obtained when cells were permeabilized electrically (R. J. H. Wojcikiewicz, and S. G. Luo, unpublished data) .
Taken together, these data indicate that the InsP 3 -independent Ca 2ϩ -handling properties of SH-SY5Y, AR4-2J, and RINm5F cells are very similar and thus the relatively high EC 50 value of InsP 3 in permeabilized RINm5F cells is a reflection of the predominance of low affinity type III receptors in this cell type.
Binding to InsP 3 receptors immunoprecipitated from rat tissues. To confirm that the differences in binding affinity seen in cultured cells are representative of the situation in vivo, we immunopurified InsP 3 receptors from rat tissues, using cerebellum and cerebral cortex as sources of type I receptor, liver as a source of type II receptor, and pancreas as a source of type III receptor. The type I receptor preparations were essentially homogeneous with no "contamination" from the faster migrating type II or III receptors (Fig. 6, lanes 1 and 2) . In contrast, it is estimated from the silver-stained and immunoblotted gels that the type II receptor preparation contains ϳ25% type I receptor (lane 3) and that the type III receptor preparation contains ϳ20% type II receptor and ϳ5% type I receptor (lane 4) [the migration position of the pancreatic type III receptor in the silverstained gel (Fig. 6, lane 4) is anomalously low due to distortion of the gel during photography; the body of data from these experiments showed that migration of the pancreatic type III receptor was between that of type I and type II receptors]. Such coimmunoprecipitation indicates that heterotetrameric InsP 3 receptors are expressed in liver and pancreas.
Initial analysis (Fig. 7A) showed that InsP 3 binding to the preparations from cortex, cerebellum, liver, and pancreas was half-maximal at 0.7, 1.2, 1.7, and 20.9 nM, respectively, with the values for liver and pancreas preparations being significantly greater ( p Յ 0.01) than that for cortex (see Fig.  7 legend) . Furthermore, although the curves for cortex and cerebellum had Hill slopes of ϳ1, those for liver (0.78 Ϯ 0.05) and pancreas (0.57 Ϯ 0.08) were significantly Ͻ1 (p Յ 0.01), indicating that multiple binding sites were present in these preparations (see Fig. 7 legend) . This also is illustrated by Scatchard analysis; the data points for liver and particularly pancreas are not related linearly (Fig. 7B) . Thus, one-site analysis was used to define K d values for binding to cortex and cerebellum preparations and two-site analysis was used to define the sites present in liver and pancreas preparations. However, two-site analysis of binding to the liver preparation did not yield consistent data, presumably because of the closeness of the affinities of type I and II receptors; thus, the liver preparation K d value was defined by one-site analysis. The K d values obtained were 0.7 Ϯ 0.1 nM for cortex, 1.2 Ϯ 0.2 nM for cerebellum, 1.8 Ϯ 0.2 nM for liver (see preceding explanation), and 0.5 Ϯ 0.1 and 43 Ϯ 1 nM for pancreas, with the latter site representing 75 Ϯ 5% of the total (at least four independent experiments).
Discussion
The major findings presented herein are that type I, II, and III InsP 3 receptors bind InsP 3 with different affinities and that these differences seem to influence the potency of InsP 3 as a Ca 2ϩ -mobilizing agent. This provides an indication of how selective expression of a particular InsP 3 receptor type will influence cell signaling. Importantly, this is the first study in which type I, II, and III receptors have been analyzed under identical experimental conditions and thus provides an accurate assessment of their differences. Our findings from cell lines and rat tissues that type I, II, and III receptors bind InsP 3 with K d values of ϳ1, ϳ2, and ϳ40 nM, respectively, are broadly in agreement with previous studies, the most significant of which also concluded that the type III receptor has relatively low affinity at physiological or subphysiological Ca 2ϩ concentrations (Newton et al., 1994; Yoneshima et al., 1997) . In some of these previous studies (Sudhof et al., 1991; Newton et al., 1994) , InsP 3 interaction with the ligand binding domains of type I, II, and III receptors was assessed, either the soluble ligand-binding domains of type I and II receptors (yielding K d values of 90 and 27 nM, respectively) or the ligand-binding domains of type I and III receptors fused to glutathione-S-transferase (yielding K d values of 6 and 67 nM, respectively). These results led to the conclusion that the rank order of affinity was type II Ͼ type I Ͼ type III (Sudhof et al., 1991; Newton et al., 1994) . Although we agree that the type III receptor has by far the lowest affinity, our conclusion is that the affinity order is type I Ͼ type II Ͼ type III. The reason for the discrepancy may be that we measured binding to whole InsP 3 receptors in tetrameric association rather than to monomeric receptor fragments; monomeric receptor fragments may bind InsP 3 differently to native receptors.
Is there a basis for the type III receptor being so different from types I and II receptors ? Over their entire sequences, type I and II receptors are 69% identical and type I and III receptors are 62% identical; in the ligand-binding domain (the amino-terminal 576 amino acids), the similarity is 77% and 73%, respectively (Mignery et al., 1990; Sudhof et al., 1991; Blondel et al., 1993; Newton et al., 1994; Joseph, 1996) . Thus, gross sequence differences do not explain the variation in K d value. Furthermore, all of the 10 basic residues within the ligand-binding domain of the type I receptor that seem to be involved in InsP 3 binding are conserved in type II and III receptors (Yoshikawa et al., 1996) . Thus, at the present, the low affinity of the type III receptor cannot be explained.
We also conclude that the affinity differences among type I, II, and III receptors contribute to setting the EC 50 value of InsP 3 as a Ca 2ϩ -mobilizing agent. Thus, the difference in K d value between type I and III receptors (ϳ40-fold) dictates that the InsP 3 receptors in permeabilized SH-SY5Y and RINm5F cells are half-maximally saturated at 25 and 260 nM, respectively (a difference of ϳ10-fold), and thus that the potency of InsP 3 will be greater in SH-SY5Y cells than in RINm5F cells (EC 50 values differ by ϳ5-fold). A similar difference has been measured between A7r5 and C 3 H10T 1/2 cells, which express predominantly type I and type III receptors, respectively (De Smedt et al., 1997) . However, our data also show that the relationship between half-maximal saturation and EC 50 value is not directly proportional. Indeed, although the binding affinity of type I receptor preparations and SH-SY5Y cells was slightly higher than that of type II receptor preparations and AR4 -2J cells, the EC 50 values for InsP 3 in SH-SY5Y and AR4 -2J cells were identical. Thus, a factor or factors other than binding affinity also must influence EC 50 ; this does not seem to be variation among the cells in Ca 2ϩ store characteristics because the InsP 3 -independent Ca 2ϩ -handling properties of the three cell types essentially were identical. Rather, InsP 3 receptor density may be the factor because it is known from transfection studies that increasing the InsP 3 receptor density increases the potency of InsP 3 (Miyawaki et al., 1990) . Because AR4 -2J and RINm5F cells have two to three times as many InsP 3 -binding sites as SH-SY5Y cells, a finding that agrees with previous immunochemical studies (Wojcikiewicz, 1995) , one would expect EC 50 values in AR4 -2J and RINm5F cells to be closer to the SH-SY5Y cell value than that predicted from binding affinity differences alone.
The overall significance of these findings is that the Ca 2ϩ stores of cells that express predominantly type II or type III receptors will be less sensitive to cell surface receptorgenerated InsP 3 than would cells expressing predominantly type I receptors. For example, hepatocytes seem to express predominantly the type II receptor (Joseph et al., 1995; Wojcikiewicz, 1995; De Smedt et al., 1997) and thus would be expected to have slightly lower sensitivity to InsP 3 than would cells (e.g., neuronal cells) that express predominantly the type I receptor Joseph, 1996) . More significant reductions in sensitivity to InsP 3 are to be expected in cells that express the type III receptor predominantly, such as pancreatic islet ␤ cells (Blondel et al., 1993 (Blondel et al., , 1994 . Remembering that variation in receptor density may compensate for or exacerbate these differences, it will be fascinating to test this hypothesis directly by comparing Ca 2ϩ release from these cell types under identical experimental conditions.
Finally, given that the sequences of type I, II, and III receptors are divergent throughout their entire lengths, it is to be expected that they will differ in ways other than in ligand binding affinity, such as in their ability to be phosphorylated. Our future studies are aimed at defining these differences.
